Bentamapimod is primarily investigated for its potential therapeutic applications in treating inflammatory diseases, neurodegenerative disorders, and certain types of cancer. It functions as a selective inhibitor of the JNK (c-Jun N-terminal kinase), a key enzyme involved in the regulation of inflammatory responses, stress signaling, and cell apoptosis pathways. By inhibiting this enzyme, it may help reduce inflammation, protect cells from abnormal death, and modulate immune responses, making it a candidate for conditions like rheumatoid arthritis, Crohn's disease, neurological diseases, autoimmune disorders, and oncology. Additionally, its role in targeting signaling pathways for liver and chronic kidney diseases is being explored to assess its efficacy in inhibiting disease progression. Research is ongoing to evaluate its safety, dosage, and effectiveness in clinical settings.